Climb Bio, Inc. (NASDAQ:CLYM) is currently trading at $2.32, with a target price of $1.80, indicating a potential downside of approximately -22.41%. This suggests that analysts are pessimistic about the stock's future performance, leading to its exclusion from coverage. Climb Bio operates in the biotechnology sector, focusing on developing innovative therapies.
In comparison, Inovio Pharmaceuticals, Inc. (INO) is trading at $2.47 with a target price of $1.96, reflecting a potential downside of -20.63%. Despite a market cap of $131.26 million, Inovio's negative earnings per share (EPS) of -2.72 and a price-to-earnings (P/E) ratio of -0.46 indicate financial challenges similar to Climb Bio.
Context Therapeutics Inc. (CNTX) presents a different scenario, with a current price of $1.37 and a target price of $1.61, suggesting a potential upside of 17.72%. With a market cap of $122.89 million, Context Therapeutics has an EPS of -0.43 and a P/E ratio of -2.30, showing a more favorable outlook compared to Climb Bio.
Inhibikase Therapeutics, Inc. (IKT) offers the highest growth potential among Climb Bio's peers. Trading at $1.61 with a target price of $2.38, it has a potential upside of 47.68%. Despite a market cap of $119.60 million, its EPS of -0.04 and P/E ratio of -2.80 suggest a more promising investment opportunity.
